Genelux (GNLX) Net Equity Issued and Repurchased (2023 - 2026)
Genelux (GNLX) posted quarterly Net Equity Issued and Repurchased of $18.5 million for Q1 2026, up 93.92% year-over-year from $9.6 million in Q1 2025, and up 93.92% quarter-over-quarter from $9.6 million in Q1 2025.
Genelux (GNLX) Net Equity Issued and Repurchased (2023 - 2026) Analysis & Trends
Genelux's Net Equity Issued and Repurchased history runs 4 years deep, the most recent figure standing at $18.5 million for Q1 2026.
- In Q1 2026, Net Equity Issued and Repurchased rose 93.92% year-over-year to $18.5 million; the TTM figure through Mar 2026 stood at $18.5 million (up 93.61% YoY), while the FY2025 annual figure was $9.6 million, down 65.5% from the prior year.
- Net Equity Issued and Repurchased for Q1 2026 stood at $18.5 million, up from $9.6 million in the prior quarter.
- The five-year high for Net Equity Issued and Repurchased was $18.5 million in Q1 2026, with the low at $15000.0 in Q4 2024.
- The 4-year median for Net Equity Issued and Repurchased is $8.3 million (2023), against an average of $8.9 million.
- Peak annual rise in Net Equity Issued and Repurchased reached 93.92% in 2026, while the deepest fall reached 93.92% in 2026.
- Genelux's Net Equity Issued and Repurchased stood at $3.5 million in 2023, then slumped by 99.57% to $15000.0 in 2024, then soared by 63586.67% to $9.6 million in 2025, then jumped by 93.92% to $18.5 million in 2026.
- Business Quant data shows GNLX's Net Equity Issued and Repurchased at $18.5 million in Q1 2026, $9.6 million in Q1 2025, and $15000.0 in Q4 2024.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Net Equity Issued and Repurchased (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | - |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | 49.20 Mn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | - |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | - |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | - |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | - |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | - |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | - |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | - |
| 10 | Genelux | 119.87 Mn | 119.87 Mn | - | 18.53 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 18.53 Mn |
| Mar 31, 2026 | 18.53 Mn |
| Mar 31, 2025 | 9.55 Mn |
| Mar 31, 2025 | 9.55 Mn |
| Dec 31, 2024 | 15,000.00 |
| Dec 31, 2024 | 15,000.00 |
| Sep 30, 2023 | 3.50 Mn |
| Sep 30, 2023 | 3.50 Mn |
| Jun 30, 2023 | 7.14 Mn |
| Jun 30, 2023 | 7.14 Mn |
| Mar 31, 2023 | 14.50 Mn |
| Mar 31, 2023 | 14.50 Mn |